Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Blood (2024) 144 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2024-211383

Published: 2024

Journal Articles

Risk of Second Cancers in Waldenstrom Macroglobulinemia: a Population-Based Study From Northern Italy.

Marzia Varettoni, Alessandra Tedeschi, Cristiana Pascutto, Eleonora Vismara, Luca Arcaini, Antonino Greco, Ester Orlandi, Francesca Ricci, Alessandro Corso, Sara Miqueleiz, Cesare Astori, Mario Lazzarino, Enrica Morra

Blood (2009) 114 (22): 3951.

https://doi.org/10.1182/blood.V114.22.3951.3951

Published: 2009

Journal Articles

Results of a Phase II Multicenter Study of Immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Symptomatic Waldenstrom’s Macroglobulinemia

Alessandra Tedeschi, Giulia Benevolo, Marzia Varettoni, Marta Battista, Sara Miqueleiz, Francesca Ricci, Michele Nichelatti, Francesco Zaja, Pier Luigi Zinzani, Vittorio Meneghini, Pietro Pioltelli, Mario Lazzarino, Umberto Vitolo, Enrica Morra

Blood (2008) 112 (11): 3692.

https://doi.org/10.1182/blood.V112.11.3692.3692

Published: 2008

Journal Articles

Impact on Progression Free Survival of Autologous Stem Cell transplantation after Consolidation with Alemtuzumab in Chronic Lymphocytic Leukemia.

Marco Montillo, Francesca Ricci, Alessandra Tedeschi, Sara Miqueleiz, Giovanni Grillo, Eleonora Vismara, Antonino Greco, Silvio Veronese, Enrica Morra

Blood (2008) 112 (11): 2182.

https://doi.org/10.1182/blood.V112.11.2182.2182

Published: 2008

Journal Articles

Transient Massive Lymphoid Bone Marrow Infiltrate Developing during Therapy with the Tyrosine Kinase Inhibitors Imatinib and Nilotinib: Report of 2 Patients.

Ester Pungolino, MD, Silvia Cantoni, MD, Cecilia Del Curto, MD, Livio Gargantini, MD, Marianna Caramella, MD, Sara Miqueleiz, MD, Alessandra Tedeschi, MD, Michela Draisci, MD, Cristina Gabutti, MD, Simona Paratore, MD, Karen Lanza, BD, Sonia Ribera, MD, Enrica Morra, MD

Blood (2007) 110 (11): 4577.

https://doi.org/10.1182/blood.V110.11.4577.4577

Published: 2007

Journal Articles

Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL).

Marco Montillo, MD, Sara Miqueleiz, MD, Alessandra Tedeschi, MD, Francesca Ricci, MD, Eleonora Vismara, MD, Denis Ciapanna, MD, Valeria Belsito Petrizzi, MD, Monica Crugnola, MD, Mauro Spriano, MD, Lilj Uziel, MD, Angelo De Blasio, MD, Pierangelo Spedini, PhD, Enrica Morra, MD

Blood (2007) 110 (11): 3133.

https://doi.org/10.1182/blood.V110.11.3133.3133

Published: 2007

Journal Articles

Intermediate Dose Ara-C Followed by G-CSF: An Effective and Predictable Mobilization Regimen in Hematological Malignancies.

Francesca Ricci, MD, Marco Montillo, MD, Alessandra Tedeschi, MD, Sara Miqueleiz, MD, Erika Ravelli, MD, Liliana Intropido, PhD, Barbara Scarapati, PhD, Enrica Morra, MD

Blood (2007) 110 (11): 3290.

https://doi.org/10.1182/blood.V110.11.3290.3290

Published: 2007

Journal Articles

Fludarabine, Cyclophosphamide and Rituximab in Waldenström’s Macroglobulinemia: An Effective Regimen Requiring a New Category of Response Criteria and a Delayed Assessment of Results

Alessandra Tedeschi, MD, Sara Miqueleiz, MD, Francesca Ricci, MD, Annalisa Luraschi, MD, Mario Schiavone, MD, Alessandro Andriani, MD, Maria Teresa Petrucci, MD, Felicetto Ferrara, MD, Enrica Morra, MD

Blood (2007) 110 (11): 1290.

https://doi.org/10.1182/blood.V110.11.1290.1290

Published: 2007

Journal Articles

Oxaliplatin as Single Agent or in Combination in Chronic Lymphocytic Leukaemia (CLL).

Marco Montillo, MD, Sara Miqueleiz, MD, Alessandra Tedeschi, MD, Francesca Ricci, MD, Alfredo Molteni, MD, Enrica Morra, MD

Blood (2006) 108 (11): 4982.

https://doi.org/10.1182/blood.V108.11.4982.4982

Published: 2006

Journal Articles

Pharmacokinetic Analysis of Subcutaneous Alemtuzumab as Consolidation Therapy To Achieve MRD-Negative Responses.

Mario Regazzi, Michela Montagna, Antonia Avanzini, Barbara Scarpati, Anna Colosimo, Silvio Veronese, Alessandra Tedeschi, Sara Miqueleiz, Francesca Ricci, Liliana Intropido, Enrica Morra, Marco Montillo

Blood (2005) 106 (11): 2962.

https://doi.org/10.1182/blood.V106.11.2962.2962

Published: 2005

Journal Articles

Purging "In Vivo" with Alemtuzumab (Campath-1H) before Autologous Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).

Marco Montillo, Alessandra Tedeschi, Roberto Cairoli, Sara Miqueleiz, Barbara Scarpati, Anna Maria Cafro, Liliana Intropido, Renata Farioli, Silvio Veronese, Enrica Morra

Blood (2005) 106 (11): 2927.

https://doi.org/10.1182/blood.V106.11.2927.2927

Published: 2005

Journal Articles

Combination of Fludarabine (FAMP) Cyclophosphamide (CTX) and Alemtuzumab for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).

Alessandra Tedeschi, Marco Montillo, Sara Miqueleiz, Michela Draisci, Francesca Ricci, Barbara Scarpati, Mariangela Mura, Monica Crugnola, Enrica Morra

Blood (2005) 106 (11): 5036.

https://doi.org/10.1182/blood.V106.11.5036.5036

Published: 2005

Journal Articles

Mobilization of Ph-Negative Peripheral Blood Stem Cells (PBSCs) with rHu-G-CSF in Chronic Myeloid Leukemia (CML) Patients Achieving Complete Cytogenetic Response with Imatinib Mesilate (Glivec).

Ester Pungolino, MD, Michela Draisci, MD, Livio Gargantini, MD, Renata Farioli, PhD, Valentina Rossi, MD, Paola Cozzi, MD, Sara Miqueleiz Alamos, MD, Anna Maria Cafro, MD, Enrica Morra, MD

Blood (2004) 104 (11): 4690.

https://doi.org/10.1182/blood.V104.11.4690.4690

Published: 2004

NARROW

Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Risk of Second Cancers in Waldenstrom Macroglobulinemia: a Population-Based Study From Northern Italy.

Results of a Phase II Multicenter Study of Immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Symptomatic Waldenstrom’s Macroglobulinemia

Impact on Progression Free Survival of Autologous Stem Cell transplantation after Consolidation with Alemtuzumab in Chronic Lymphocytic Leukemia.

Transient Massive Lymphoid Bone Marrow Infiltrate Developing during Therapy with the Tyrosine Kinase Inhibitors Imatinib and Nilotinib: Report of 2 Patients.

Combined Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC), an Active Regimen for Treated Patients with Chronic Lymphocytic Leukemia (CLL).

Intermediate Dose Ara-C Followed by G-CSF: An Effective and Predictable Mobilization Regimen in Hematological Malignancies.

Fludarabine, Cyclophosphamide and Rituximab in Waldenström’s Macroglobulinemia: An Effective Regimen Requiring a New Category of Response Criteria and a Delayed Assessment of Results

Oxaliplatin as Single Agent or in Combination in Chronic Lymphocytic Leukaemia (CLL).

Pharmacokinetic Analysis of Subcutaneous Alemtuzumab as Consolidation Therapy To Achieve MRD-Negative Responses.

Purging "In Vivo" with Alemtuzumab (Campath-1H) before Autologous Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).

Combination of Fludarabine (FAMP) Cyclophosphamide (CTX) and Alemtuzumab for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).

Mobilization of Ph-Negative Peripheral Blood Stem Cells (PBSCs) with rHu-G-CSF in Chronic Myeloid Leukemia (CML) Patients Achieving Complete Cytogenetic Response with Imatinib Mesilate (Glivec).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only